Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation

NCT03474614 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped lack of accrual

Conditions

Cerebral Cavernous Malformations

Interventions

DRUG: Propranolol
GENETIC: DNA and RNA Analysis

Sponsor

St. Joseph's Hospital and Medical Center, Phoenix